---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-015426"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2023-09-05T23:59:59+00:00"
generated_at: "2026-06-11T00:10:46.251422+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics appoints new President, CMO, CDO; Huber resigns to pursue CEO role

## Summary
- Martin Huber, M.D., resigns as President and Head of R&D effective Sept 8; remains advisor.
- CEO René Russo adds President title; previously served as President in 2021-2022.
- Katarina Luptakova promoted to CMO; succeeds Huber with 20 years of oncology drug development experience.
- Scott Coleman promoted to CDO; over 25 years in biotech, including at Acceleron and Merck.
- Kevin Brennan enters employment agreement (base $370K, 35% bonus target) as SVP Finance.

## SEC filing metadata
- accession: 0001558370-23-015426
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2023-09-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837023015426/0001558370-23-015426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837023015426/xlo-20230830x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-015426
- JSON: https://secwatch.observer/filing/0001558370-23-015426.json
- Plain text: https://secwatch.observer/filing/0001558370-23-015426.txt

## Key facts
- Executive change
  René Russo was appointed as President at Xilio Therapeutics, Inc..
  - Action: appointed
  - Role: President
  source text: Effective September 8, 2023, the board of directors (the “Board”) of the Company appointed René Russo, Pharm.D., 48, to President of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837023015426/0001558370-23-015426-index.htm
- Executive change
  Martin Huber resigned as President and Head of Research and Development at Xilio Therapeutics, Inc..
  - Action: resigned
  - Role: President and Head of Research and Development
  source text: Martin Huber, M.D., notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as President and Head of Research and Development of the Company, effective September 8, 2023, to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837023015426/0001558370-23-015426-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.